Skip to main content

Table 2 TNF inhibitor (TNFi) treatment in patients with and without fibromyalgia

From: Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis

  Total number of patients Fibromyalgia+ Fibromyalgia- P
(n = 196) (n = 42) (n = 154)
Patients who received at least one TNFi 141 (71.9 %) 33 (78.6 %) 108 (70.1 %) 0.28
 Number of TNFi treatments 1.84 (1.0) 2.36 (1.1) 1.68 (0.9) <0.01
 Switchers* 9 (6.5 %) 5 (15.2 %) 4 (3.8 %) 0.03
First TNFi
 Mean duration of first TNFi treatment, years 3.0 (3.8) 1.7 (2.4) 3.5 (4.0) <0.01
 Reason for TNFi discontinuation:
 Inefficacy % 54 (69.2 %) 12 (54.6 %) 42 (75.0 %) 0.14
 Toxicity % 4 (5.1 %) 2 (9.1 %) 2 (3.6 %) 0.76
 Inefficacy + toxicity % 4 (5.1 %) 3 (13.6 %) 1 (1.8 %) 0.23
 Others % 16 (20.5 %) 5 (22.7 %) 11 (19.6 %) 1.00
  1. All results are presented as mean ± SD for continuous variables or number (%) for categorical variables. Fibromyalgia + was defined as a Fibromyalgia Rapid Screening Tool (FiRST) score ≥5/6. *Patients who received ≥3 TNFi within ≤12 months